Our Pipeline

A Deep, Broad Pipeline to Address Unmet Patient Need

Our deep and broad pipeline contains multiple clinical-stage and preclinical candidates for diseases with significant unmet patient need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world. 

RSV program out-licensed to GSK

HIV: Human Immunodeficiency Virus; RSV: Respiratory Syncytial Virus; PEG-IFN-α: peg-interferon alfa-2a; mAb: monoclonal antibody. Tobevibart incorporates Xencor’s Xtend™ and other Fc technologies.